Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Cardiac rehabilitation after acute myocardial infarction in Sweden - evaluation of programme characteristics and adherence to European guidelines: The Perfect Cardiac Rehabilitation (Perfect-CR) study.

Ögmundsdottir Michelsen H, Sjölin I, Schlyter M, Hagström E, Kiessling A, Henriksson P, Held C, Hag E, Nilsson L, Bäck M, Schiopu A, Zaman MJ, Leosdottir M.

Eur J Prev Cardiol. 2019 Jul 26:2047487319865729. doi: 10.1177/2047487319865729. [Epub ahead of print]

PMID:
31349776
2.

Inhibition of pro-inflammatory myeloid cell responses by short-term S100A9 blockade improves cardiac function after myocardial infarction.

Marinković G, Grauen Larsen H, Yndigegn T, Szabo IA, Mares RG, de Camp L, Weiland M, Tomas L, Goncalves I, Nilsson J, Jovinge S, Schiopu A.

Eur Heart J. 2019 Jul 10. pii: ehz461. doi: 10.1093/eurheartj/ehz461. [Epub ahead of print]

PMID:
31292614
3.

The soluble receptor for advanced glycation end-products (sRAGE) has a dual phase-dependent association with residual cardiovascular risk after an acute coronary event.

Grauen Larsen H, Yndigegn T, Marinkovic G, Grufman H, Mares R, Nilsson J, Goncalves I, Schiopu A.

Atherosclerosis. 2019 May 24;287:16-23. doi: 10.1016/j.atherosclerosis.2019.05.020. [Epub ahead of print]

PMID:
31181415
4.

High Plasma sRAGE (Soluble Receptor for Advanced Glycation End Products) Is Associated With Slower Carotid Intima-Media Thickness Progression and Lower Risk for First-Time Coronary Events and Mortality.

Grauen Larsen H, Marinkovic G, Nilsson PM, Nilsson J, Engström G, Melander O, Orho-Melander M, Schiopu A.

Arterioscler Thromb Vasc Biol. 2019 May;39(5):925-933. doi: 10.1161/ATVBAHA.118.312319.

PMID:
30917679
5.
6.

Tailored nurse-led cardiac rehabilitation after myocardial infarction results in better risk factor control at one year compared to traditional care: a retrospective observational study.

Ögmundsdottir Michelsen H, Nilsson M, Scherstén F, Sjölin I, Schiopu A, Leosdottir M.

BMC Cardiovasc Disord. 2018 Aug 15;18(1):167. doi: 10.1186/s12872-018-0907-0.

7.

Anti-ApoA-I IgG antibodies are not associated with carotid artery disease progression and first-time cardiovascular events in middle-aged individuals.

Lagerstedt JO, Dalla-Riva J, Marinkovic G, Del Giudice R, Engelbertsen D, Burlin J, Petrlova J, Lindahl M, Bernfur K, Melander O, Nilsson J, Schiopu A.

J Intern Med. 2019 Jan;285(1):49-58. doi: 10.1111/joim.12817. Epub 2018 Aug 7.

PMID:
30028049
8.

Elevated IL-27 in patients with acute coronary syndrome is associated with adverse ventricular remodeling and increased risk of recurrent myocardial infarction and cardiovascular death.

Grufman H, Yndigegn T, Gonçalves I, Nilsson J, Schiopu A.

Cytokine. 2018 Feb 7:154208. doi: 10.1016/j.cyto.2017.11.002. [Epub ahead of print]

PMID:
29428559
9.

Stress-induced release of the S100A8/A9 alarmin is elevated in coronary artery disease patients with impaired cortisol response.

Jonasson L, Grauen Larsen H, Lundberg AK, Gullstrand B, Bengtsson AA, Schiopu A.

Sci Rep. 2017 Dec 13;7(1):17545. doi: 10.1038/s41598-017-17586-6.

10.

IL-1R and MyD88 signalling in CD4+ T cells promote Th17 immunity and atherosclerosis.

Engelbertsen D, Rattik S, Wigren M, Vallejo J, Marinkovic G, Schiopu A, Björkbacka H, Nilsson J, Bengtsson E.

Cardiovasc Res. 2018 Jan 1;114(1):180-187. doi: 10.1093/cvr/cvx196.

PMID:
29036304
11.

A 0-Hour/1-Hour Protocol for Safe, Early Discharge of Chest Pain Patients.

Mokhtari A, Lindahl B, Schiopu A, Yndigegn T, Khoshnood A, Gilje P, Ekelund U.

Acad Emerg Med. 2017 Aug;24(8):983-992. doi: 10.1111/acem.13224. Epub 2017 Jul 26.

12.

Associations Between Macrophage Colony-Stimulating Factor and Monocyte Chemotactic Protein 1 in Plasma and First-Time Coronary Events: A Nested Case-Control Study.

Schiopu A, Bengtsson E, Gonçalves I, Nilsson J, Fredrikson GN, Björkbacka H.

J Am Heart Assoc. 2016 Sep 13;5(9). pii: e002851. doi: 10.1161/JAHA.115.002851.

13.

A high quality diet is associated with reduced systemic inflammation in middle-aged individuals.

Dias JA, Wirfält E, Drake I, Gullberg B, Hedblad B, Persson M, Engström G, Nilsson J, Schiopu A, Fredrikson GN, Björkbacka H.

Atherosclerosis. 2015 Jan;238(1):38-44. doi: 10.1016/j.atherosclerosis.2014.11.006. Epub 2014 Nov 13.

PMID:
25437888
14.

High plasma levels of heparin-binding epidermal growth factor are associated with a more stable plaque phenotype and reduced incidence of coronary events.

Rattik S, Wigren M, Björkbacka H, Fredrikson GN, Hedblad B, Siegbahn A, Bengtsson E, Schiopu A, Edsfeldt A, Dunér P, Grufman H, Gonçalves I, Nilsson J.

Arterioscler Thromb Vasc Biol. 2015 Jan;35(1):222-8. doi: 10.1161/ATVBAHA.114.304369. Epub 2014 Oct 30.

PMID:
25359857
15.

Evidence for altered inflammatory and repair responses in symptomatic carotid plaques from elderly patients.

Grufman H, Schiopu A, Edsfeldt A, Björkbacka H, Nitulescu M, Nilsson M, Persson A, Nilsson J, Gonçalves I.

Atherosclerosis. 2014 Nov;237(1):177-82. doi: 10.1016/j.atherosclerosis.2014.08.042. Epub 2014 Sep 6.

PMID:
25240113
16.

Multi-radionuclide digital autoradiography of the intra-aortic atherosclerotic plaques using a monoclonal antibody targeting oxidized low-density lipoprotein.

Orbom A, Jansson B, Schiopu A, Evans-Axelsson S, Nilsson J, Fredrikson GN, Strand SE.

Am J Nucl Med Mol Imaging. 2014 Mar 20;4(2):172-80. eCollection 2014.

17.

S100A8 and S100A9: DAMPs at the crossroads between innate immunity, traditional risk factors, and cardiovascular disease.

Schiopu A, Cotoi OS.

Mediators Inflamm. 2013;2013:828354. doi: 10.1155/2013/828354. Epub 2013 Dec 22. Review.

18.

Plasma S100A8/A9 correlates with blood neutrophil counts, traditional risk factors, and cardiovascular disease in middle-aged healthy individuals.

Cotoi OS, Dunér P, Ko N, Hedblad B, Nilsson J, Björkbacka H, Schiopu A.

Arterioscler Thromb Vasc Biol. 2014 Jan;34(1):202-10. doi: 10.1161/ATVBAHA.113.302432. Epub 2013 Nov 7.

PMID:
24202303
19.

Plasma procalcitonin is associated with all-cause and cancer mortality in apparently healthy men: a prospective population-based study.

Cotoi OS, Manjer J, Hedblad B, Engström G, Melander O, Schiopu A.

BMC Med. 2013 Aug 13;11:180. doi: 10.1186/1741-7015-11-180.

20.

Ly-6C(hi) monocytes: a potential target for preventing transplant arteriosclerosis?

Schiopu A, Cotoi OS, Wood KJ.

Expert Rev Clin Immunol. 2013 Jan;9(1):5-7. doi: 10.1586/eci.12.90. No abstract available.

PMID:
23256758
21.

Inflammatory Ly-6C(hi) monocytes play an important role in the development of severe transplant arteriosclerosis in hyperlipidemic recipients.

Schiopu A, Nadig SN, Cotoi OS, Hester J, van Rooijen N, Wood KJ.

Atherosclerosis. 2012 Aug;223(2):291-8. doi: 10.1016/j.atherosclerosis.2012.05.010. Epub 2012 May 19.

22.

Plasma procalcitonin and the risk of cardiovascular events and death: a prospective population-based study.

Schiopu A, Hedblad B, Engström G, Struck J, Morgenthaler NG, Melander O.

J Intern Med. 2012 Nov;272(5):484-91. doi: 10.1111/j.1365-2796.2012.02548.x. Epub 2012 May 21.

23.

Low-dose rapamycin treatment increases the ability of human regulatory T cells to inhibit transplant arteriosclerosis in vivo.

Hester J, Schiopu A, Nadig SN, Wood KJ.

Am J Transplant. 2012 Aug;12(8):2008-16. doi: 10.1111/j.1600-6143.2012.04065.x. Epub 2012 Apr 14.

24.

Functional regulatory T cells produced by inhibiting cyclic nucleotide phosphodiesterase type 3 prevent allograft rejection.

Feng G, Nadig SN, Bäckdahl L, Beck S, Francis RS, Schiopu A, Whatcott A, Wood KJ, Bushell A.

Sci Transl Med. 2011 May 18;3(83):83ra40. doi: 10.1126/scitranslmed.3002099.

25.

Adsorption of low-density lipoprotein, its oxidation, and subsequent binding of specific recombinant antibodies: An in situ ellipsometric study.

Stollenwerk MM, Svensson O, Schiopu A, Jansson B, Arnebrant T, Fredrikson GN.

Biochim Biophys Acta. 2011 Feb;1810(2):211-7. doi: 10.1016/j.bbagen.2010.10.006. Epub 2010 Oct 20.

PMID:
20970483
26.

In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells.

Nadig SN, Wieckiewicz J, Wu DC, Warnecke G, Zhang W, Luo S, Schiopu A, Taggart DP, Wood KJ.

Nat Med. 2010 Jul;16(7):809-13. doi: 10.1038/nm.2154. Epub 2010 May 16.

27.

Role of T cells in graft rejection and transplantation tolerance.

Issa F, Schiopu A, Wood KJ.

Expert Rev Clin Immunol. 2010 Jan;6(1):155-69. Review.

PMID:
20383898
28.

Regulatory T cells: hypes and limitations.

Schiopu A, Wood KJ.

Curr Opin Organ Transplant. 2008 Aug;13(4):333-8. doi: 10.1097/MOT.0b013e3283061137. Review.

PMID:
18685326
29.

Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice.

Schiopu A, Frendéus B, Jansson B, Söderberg I, Ljungcrantz I, Araya Z, Shah PK, Carlsson R, Nilsson J, Fredrikson GN.

J Am Coll Cardiol. 2007 Dec 11;50(24):2313-8. Epub 2007 Nov 26.

30.

Oxidized LDL antibodies in treatment and risk assessment of atherosclerosis and associated cardiovascular disease.

Nilsson J, Nordin Fredrikson G, Schiopu A, Shah PK, Jansson B, Carlsson R.

Curr Pharm Des. 2007;13(10):1021-30. Review.

PMID:
17430165
31.

Association between IgM against an aldehyde-modified peptide in apolipoprotein B-100 and progression of carotid disease.

Fredrikson GN, Hedblad B, Berglund G, Alm R, Nilsson JA, Schiopu A, Shah PK, Nilsson J.

Stroke. 2007 May;38(5):1495-500. Epub 2007 Mar 15.

PMID:
17363723
32.

Autoantibody against the amino acid sequence 661-680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events.

Fredrikson GN, Schiopu A, Berglund G, Alm R, Shah PK, Nilsson J.

Atherosclerosis. 2007 Oct;194(2):e188-92. Epub 2007 Jan 9.

PMID:
17214995
33.

Inhibition of injury-induced arterial remodelling and carotid atherosclerosis by recombinant human antibodies against aldehyde-modified apoB-100.

Ström A, Fredrikson GN, Schiopu A, Ljungcrantz I, Söderberg I, Jansson B, Carlsson R, Hultgårdh-Nilsson A, Nilsson J.

Atherosclerosis. 2007 Feb;190(2):298-305. Epub 2006 May 4.

PMID:
16677655
34.

Very low density lipoprotein potentiates tumor necrosis factor-alpha expression in macrophages.

Stollenwerk MM, Schiopu A, Fredrikson GN, Dichtl W, Nilsson J, Ares MP.

Atherosclerosis. 2005 Apr;179(2):247-54. Epub 2005 Jan 19.

PMID:
15777538
35.

Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis.

Schiopu A, Bengtsson J, Söderberg I, Janciauskiene S, Lindgren S, Ares MP, Shah PK, Carlsson R, Nilsson J, Fredrikson GN.

Circulation. 2004 Oct 5;110(14):2047-52. Epub 2004 Sep 27.

PMID:
15451805

Supplemental Content

Loading ...
Support Center